# Talotrexin in Treating Young Patients With Recurrent Solid Tumors or Leukemia That is Recurrent or Does Not Respond to Treatment

> **NCT00458744** · PHASE1 · WITHDRAWN · sponsor: **Children's Oncology Group**

## Conditions studied

- Brain and Central Nervous System Tumors
- Leukemia
- Lymphoma
- Unspecified Childhood Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** talotrexin
- **PROCEDURE:** chemotherapy

## Key facts

- **NCT ID:** NCT00458744
- **Lead sponsor:** Children's Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2007-02
- **Primary completion:** 2008-07
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study withdrawn because of toxicity reported on the adult phase 1 trial.
- **Last updated:** 2014-08-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00458744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00458744, "Talotrexin in Treating Young Patients With Recurrent Solid Tumors or Leukemia That is Recurrent or Does Not Respond to Treatment". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00458744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*